Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | KLK8 | O60259 | 2/20 | 0.34 |
| ▸ | PLAU | P00749 | 2/20 | 0.34 |
| ▸ | KLK2 | P20151 | 2/20 | 0.34 |
| ▸ | KLK4 | Q9Y5K2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL778383 | 0.84 | ALDH1A1 (0.52) | SMN1; SMN2CYP2C19PPARGPPARATSHR | |
| SCHEMBL777615 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP2C19THRBTSHRALDH1A1 | |
| SCHEMBL11365424 | 0.82 | PTPN1 (0.38) | LTA4HSMN1; SMN2CYP2C19MEN1KMT2A | |
| SCHEMBL780821 | 0.79 | ALDH1A1 (0.41) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL22322014 | 0.79 | ALDH1A1 (0.48) | SMN1; SMN2TSHRALDH1A1TP53CYP3A4 | |
| SCHEMBL777593 | 0.79 | CYP3A4 (0.53) | TSHRALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL780979 | 0.78 | SRC (0.47) | SMN1; SMN2CYP2C19KLK8PLAUKLK2 | |
| SCHEMBL17115761 | 0.77 | CA1 (0.39) | LTA4HSMN1; SMN2CYP2C19PPARGPPARA | |
| SCHEMBL2735734 | 0.76 | — | — | |
| SCHEMBL1982061 | 0.75 | TSHR (0.52) | LTA4HSMN1; SMN2CYP2C19PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | LTA4H 1498/4885SMN1; SMN2 3374/4885CYP2C19 4270/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | LTA4H 154/4885SMN1; SMN2 4578/4885CYP2C19 1353/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | LTA4H 1533/4885SMN1; SMN2 3324/4885CYP2C19 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.